Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension.

ABSTRACT: Background:This was a phase 3, randomized, double-blind, placebo-controlled study. Methods:Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ?150 and ?180 mmHg were randomized to 6-week treatment with placebo (n =?65), azilsartan medoxomil (AZL-M) 40 mg (n =?132), or AZL-M 80 mg (n =?131). The primary endpoint was the change from baseline to week 6 in trough scSBP. Results:The least-squares mean (standard error) change from baseline in trough scSBP in the placebo, AZL-M 40-mg, and 80-mg groups at week 6 were -?8.8 (2.00), -?22.1 (1.41), and -?23.7 (1.40) mmHg, respectively (p 

SUBMITTER: Juhasz A 

PROVIDER: S-EPMC5804062 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature